Toward novel vaccines and therapies based on negative-strand RNA viruses

Current Topics in Microbiology and Immunology

Volumn 283, Issue , 2004, Pages 281-312

  Von Messling, V ^a   Cattaneo, R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CANCER VACCINE; CIRCUMSPOROZOITE PROTEIN; ENVELOPE PROTEIN; EPITOPE; GAG PROTEIN; GLYCOPROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GUANINE NUCLEOTIDE BINDING PROTEIN; HN PROTEIN; HYBRID PROTEIN; INFLUENZA VACCINE; INTERLEUKIN 4; LIVE VACCINE; NEWCASTLE DISEASE VACCINE; ONCOLYTIC VIRUS; PEPTIDE; PEPTIDE 10; PROTEIN HA; PROTEIN RV; RECOMBINANT PROTEIN; THYMIDINE KINASE; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS NUCLEOPROTEIN; VIRUS VACCINE; VIRUS VECTOR;

CANCER; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; FLU LIKE SYNDROME; GENE MUTATION; GENETIC ANALYSIS; GENETIC ENGINEERING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEASLES VIRUS; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PARAINFLUENZA VIRUS 1; PARAINFLUENZA VIRUS 2; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE GENETICS; REVIEW; RHABDOVIRUS; RNA VIRUS; SIDE EFFECT; VESICULAR STOMATITIS VIRUS; VIRAL GENETICS; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS RECOMBINANT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PARAINFLUENZA VIRUS 1; HUMAN PARAINFLUENZA VIRUS 2; HUMAN PARAINFLUENZA VIRUS 3; INFLUENZA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MEASLES VIRUS; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE; RHABDOVIRIDAE; RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

EID: 2442704214     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-662-06099-5_8     Document Type: Review

References (102)

1. Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G., Wyatt, L. S., Candido, M. A., Kozyr, N. L., Earl, P. L., Smith, J. M., Ma, H. L., Grimm, B. D., Hulsey, M. L., Miller, J., McClure, H. M., McNicholl, J. M., Moss, B., and Robinson, H. L. (2001). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292(5514), 69-74
2. Balachandran, S., and Barber, G. N. (2000). Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50(2), 135-8
3. Balachandran, S., Porosnicu, M., and Barber, G. N. (2001). Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 75(7), 3474-9
4. Batliwalla, F. M., Bateman, B. A., Serrano, D., Murray, D., Macphail, S., Maino, V. C., Ansel, J. C., Gregersen, P. K., and Armstrong, C. A. (1998). A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4(12), 783-94
5. Bluming, A. Z., and Ziegler, J. L. (1971). Regression of Burkitt's lymphoma in association with measles infection. Lancet 2(7715), 105-6
6. Bucheit, A. D., Kumar, S., Grote, D., Lin, Y., von Messling, V., Cattaneo, R., and Fielding, A. K. (2003). An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 7(1), 62-72
7. Buchholz, U. J., Granzow, H., Schuldt, K., Whitehead, S. S., Murphy, B. R., and Collins, P. L. (2000). Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. J Virol 74(3), 1187-99
8. Bukreyev, A., Camargo, E., and Collins, P. L. (1996). Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol 70(10), 6634-41
9. Castrucci, M. R., Hou, S., Doherty, P. C., and Kawaoka, Y. (1994). Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes. J Virol 68(6), 3486-90
10. Cattaneo, R., Rebmann, G., Schmid, A., Baczko, K., ter Meulen, V., and Billeter, M. A. (1987). Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J 6(3), 681-8
11. Chua, K. B., Goh, K. J., Wong, K. T., Kamarulzaman, A., Tan, P. S., Ksiazek, T. G., Zaki, S. R., Paul, G., Lam, S. K., and Tan, C. T. (1999). Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 354(9186), 1257-9
12. Clements, C. J., and Cutts, F. T. (1995). The epidemiology of measles: thirty years of vaccination. Curr Top Microbiol Immunol 191, 13-33
13. Dahlberg, J. E., and Simon, E. H. (1969). Physical and genetic studies of Newcastle disease virus: evidence for multiploid particles. Virology 38(4), 666-78
14. Dummer, R., Dobbeling, U., Geertsen, R., Willers, J., Burg, G., and Pavlovic, J. (2001). Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication. Blood 97(2), 523-7
15. Durbin, A. P., McAuliffe, J. M., Collins, P. L., and Murphy, B. R. (1999). Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 261(2), 319-30
16. Durbin, A. P., Skiadopoulos, M. H., McAuliffe, J. M., Riggs, J. M., Surman, S. R., Collins, P. L., and Murphy, B. R. (2000). Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol 74(15), 6821-31
17. Ferko, B., Katinger, D., Grassauer, A., Egorov, A., Romanova, J., Niebler, B., Katinger, H., and Muster, T. (1998). Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis 178(5), 1359-68
18. Fernandez, M., Porosnicu, M., Markovic, D., and Barber, G. N. (2002). Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 76(2), 895-904
19. Flanagan, E. B., Zamparo, J. M., Ball, L. A., Rodriguez, L. L., and Wertz, G. W. (2001). Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol 75(13), 6107-14
20. Fodor, E., Devenish, L., Engelhardt, O. G., Palese, P., Brownlee, G. G., and Garcia-Sastre, A. (1999). Rescue of influenza A virus from recombinant DNA. J Virol 73(11), 9679-82
21. Foley, H. D., McGettigan, J. P., Siler, C. A., Dietzschold, B., and Schnell, M. J. (2000). A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc Natl Acad Sci USA 97(26), 14680-5
22. Foley, H. D., Otero, M., Orenstein, J. M., Pomerantz, R. J., and Schnell, M. J. (2002). Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J Virol 76(1), 19-31
23. Garcia-Sastre, A., Muster, T., Barclay, W. S., Percy, N., and Palese, P. (1994a). Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus. J Virol 68(10), 6254-61
24. Garcia-Sastre, A., Percy, N., Barclay, W., and Palese, P. (1994b). Introduction of foreign sequences into the genome of influenza A virus. Dev Biol Stand 82, 237-46
25. Gilleland, H. E., Jr., Gilleland, L. B., Staczek, J., Harty, R. N., Garcia-Sastre, A., Engelhardt, O. G., and Palese, P. (1997). Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa. Behring Inst Mitt(98), 291-301
26. Gonzalo, R. M., Rodriguez, D., Garcia-Sastre, A., Rodriguez, J. R., Palese, P., and Esteban, M. (1999). Enhanced CD+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine 17(7-8), 887-92
27. Grote, D., Russell, S. J., Cornu, T. I., Cattaneo, R., Vile, R., Poland, G. A., and Fielding, A. K. (2001). Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97(12), 3746-54
28. Haglund, K., Forman, J., Krausslich, H. G., and Rose, J. K. (2000). Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268(1), 112-21
29. Hammond, A. L., Plemper, R. K., Zhang, J., Schneider, U., Russell, S. J., and Cattaneo, R. (2001). Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 75(5), 2087-96
30. Hatta, M., Gao, P., Halfmann, P., and Kawaoka, Y. (2001). Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293(5536), 1840-2
31. Hosaka, Y., Kitano, H., and Ikeguchi, S. (1966). Studies on the pleomorphism of HVJ virons. Virology 29(2), 205-21
32. Iverson, L. E., and Rose, J. K. (1981). Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 23(2), 477-84
33. Kahn, J. S., Roberts, A., Weibel, C., Buonocore, L., and Rose, J. K. (2001). Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75(22), 11079-87
34. Kahn, J. S., Schnell, M. J., Buonocore, L., and Rose, J. K. (1999). Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 254(1), 81-91
35. Kalyan, N. K., Lee, S. G., Wilhelm, J., Pisano, M. R., Hum, W. T., Hsiao, C. L., Davis, A. R., Eichberg, J. W., Robert-Guroff, M., and Hung, P. P. (1994). Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1. Vaccine 12(8), 753-60
36. Kano, M., Matano, T., Kato, A., Nakamura, H., Takeda, A., Suzaki, Y., Ami, Y., Terao, K., and Nagai, Y. (2002). Primary replication of a recombinant Sendai virus vector in macaques. J Gen Virol 83(Pt 6), 1377-86
37. Karron, R. A., Buonagurio, D. A., Georgiu, A. F., Whitehead, S. S., Adamus, J. E., Clements-Mann, M. L., Harris, D. O., Randolph, V. B., Udem, S. A., Murphy, B. R., and Sidhu, M. S. (1997). Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA 94(25), 13961-6
38. Kato, A., Kiyotani, K., Sakai, Y., Yoshida, T., and Nagai, Y. (1997). The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J 16(3), 578-587
39. Kretzschmar, E., Buonocore, L., Schnell, M. J., and Rose, J. K. (1997). High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol 71(8), 5982-9
40. Kurotani, A., Kiyotani, K., Kato, A., Shioda, T., Sakai, Y., Mizumoto, K., Yoshida, T., and Nagai, Y. (1998). Sendai virus C proteins are categorically nonessential gene products but silencing their expression severely impairs viral replication and pathogenesis. Genes Cells 3(2), 111-124
41. Li, S., Polonis, V., Isobe, H., Zaghouani, H., Guinea, R., Moran, T., Bona, C., and Palese, P. (1993a). Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol 67(11), 6659-66
42. Li, S., Rodrigues, M., Rodriguez, D., Rodriguez, J. R., Esteban, M., Palese, P., Nussenzweig, R. S., and Zavala, F. (1993b). Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 90(11), 5214-8
43. Luytjes, W., Krystal, M., Enami, M., Pavin, J. D., and Palese, P. (1989). Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59(6), 1107-13
44. Matano, T., Kano, M., Nakamura, H., Takeda, A., and Nagai, Y. (2001). Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol 75(23), 11891-6
45. McGettigan, J. P., Foley, H. D., Belyakov, I. M., Berzofsky, J. A., Pomerantz, R. J., and Schnell, M. J. (2001). Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol 75(9), 4430-4
46. Mebatsion, T., and Conzelmann, K. K. (1996). Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Proc Natl Acad Sci USA 93(21), 11366-70
47. Mebatsion, T., Finke, S., Weiland, F., and Conzelmann, K. K. (1997). A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 90(5), 841-7
48. Miyahira, Y., Garcia-Sastre, A., Rodriguez, D., Rodriguez, J. R., Murata, K., Tsuji, M., Palese, P., Esteban, M., Zavala, F., and Nussenzweig, R. S. (1998). Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci USA 95(7), 3954-9
49. Moss, W. J., Cutts, F., and Griffin, D. E. (1999). Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis 29(1), 106-12
50. Neumann, G., Watanabe, T., Ito, H., Watanabe, S., Goto, H., Gao, P., Hughes, M., Perez, D. R., Donis, R., Hoffmann, E., Hobom, G., and Kawaoka, Y. (1999). Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 96(16), 9345-50
51. Ockert, D., Schirrmacher, V., Beck, N., Stoelben, E., Ahlert, T., Flechtenmacher, J., Hagmuller, E., Buchcik, R., Nagel, M., and Saeger, H. D. (1996). Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 2(1), 21-8
52. Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O'Neil, J. D., Groene, W. S., Roberts, M. S., Rabin, H., Bamat, M. K., and Lorence, R. M. (2002). Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20(9), 2251-66
53. Peng, K.-W., Donovan, K. A., Schneider, U., Cattaneo, R., Lust, J. A., and Russell, S. J. (2003). Oncolytic measles virus displaying a single chain antibody against CD38, a myeloma cell marker. Blood 101(7), 2557-62
54. Peng, K. W., Ahmann, G. J., Pham, L., Greipp, P. R., Cattaneo, R., and Russell, S. J. (2001). Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98(7), 2002-7
55. Percy, N., Barclay, W. S., Garcia-Sastre, A., and Palese, P. (1994). Expression of a foreign protein by influenza A virus. J Virol 68(7), 4486-92
56. Phuangsab, A., Lorence, R. M., Reichard, K. W., Peeples, M. E., and Walter, R. J. (2001). Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 172(1), 27-36
57. Quinones-Kochs, M. I., Schnell, M. J., Buonocore, L., and Rose, J. K. (2001). Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses. Virology 287(2), 427-35
58. Rager, M., Vongpunsawad, S., Duprex, W. P., and Cattaneo, R. (2002). Polyploid measles virus with hexameric genome length. EMBO J 21(10), 2364-72
59. Restifo, N. P., Surman, D. R., Zheng, H., Palese, P., Rosenberg, S. A., and Garcia-Sastre, A. (1998). Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. Virology 249(1), 89-97
60. Ring, C. J. (2002). Cytolytic viruses as potential anti-cancer agents. J Gen Virol 83 (Pt 3), 491-502
61. Roberts, A., Buonocore, L., Price, R., Forman, J., and Rose, J. K. (1999). Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73(5), 3723-32
62. Roberts, A., Kretzschmar, E., Perkins, A. S., Forman, J., Price, R., Buonocore, L., Kawaoka, Y., and Rose, J. K. (1998). Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72(6), 4704-11
63. Rose, N. F., Marx, P. A., Luckay, A., Nixon, D. F., Moretto, W. J., Donahoe, S. M., Montefiori, D., Roberts, A., Buonocore, L., and Rose, J. K. (2001). An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106(5), 539-49
64. Rose, N. F., Roberts, A., Buonocore, L., and Rose, J. K. (2000). Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 74(23), 10903-10
65. Russell, S. J. (1994). Replicating vectors for cancer therapy: a question of strategy. Semin Cancer Biol 5(6), 437-43
66. Sakai, Y., Kiyotani, K., Fukumura, M., Asakawa, M., Kato, A., Shioda, T., Yoshida, T., Tanaka, A., Hasegawa, M., and Nagai, Y. (1999). Accommodation of foreign genes into the Sendai virus genome: sizes of inserted genes and viral replication. FEBS Lett 456(2), 221-6
67. Schirrmacher, V., Griesbach, A., and Ahlert, T. (2001). Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol 18(5), 945-52
68. Schirrmacher, V., Haas, C., Bonifer, R., Ahlert, T., Gerhards, R., and Ertel, C. (1999). Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6(1), 63-73
69. Schlereth, B., Rose, J. K., Buonocore, L., ter Meulen, V., and Niewiesk, S. (2000). Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 74(10), 4652-7
70. Schmidt, A. C., McAuliffe, J. M., Huang, A., Surman, S. R., Bailly, J. E., Elkins, W. R., Collins, P. L., Murphy, B. R., and Skiadopoulos, M. H. (2000). Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74(19), 8922-9
71. Schneider, U., Bullough, F., Vongpunsawad, S., Russell, S. J., and Cattaneo, R. (2000). Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol 74(21), 9928-36
72. Schnell, M. J., Buonocore, L., Boritz, E., Ghosh, H. P., Chernish, R., and Rose, J. K. (1998). Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J 17(5), 1289-96
73. Schnell, M. J., Buonocore, L., Kretzschmar, E., Johnson, E., and Rose, J. K. (1996). Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci USA 93(21), 11359-65
74. Schnell, M. J., Foley, H. D., Siler, C. A., McGettigan, J. P., Dietzschold, B., and Pomerantz, R. J. (2000). Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci USA 97(7), 3544-9
75. Schnell, M. J., Johnson, J. E., Buonocore, L., and Rose, J. K. (1997). Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90(5), 849-57
76. Shiotani, A., Fukumura, M., Maeda, M., Hou, X., Inoue, M., Kanamori, T., Komaba, S., Washizawa, K., Fujikawa, S., Yamamoto, T., Kadono, C., Watabe, K., Fukuda, H., Saito, K., Sakai, Y., Nagai, Y., Kanzaki, J., and Hasegawa, M. (2001). Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector. Gene Ther 8(14), 1043-50
77. Shiver, J. W., Fu, T. M., Chen, L., Casimiro, D. R., Davies, M. E., Evans, R. K., Zhang, Z. Q., Simon, A. J., Trigona, W. L., Dubey, S. A., Huang, L., Harris, V. A., Long, R. S., Liang, X., Handt, L., Schleif, W. A., Zhu, L., Freed, D. C., Persaud, N. V., Guan, L., Punt, K. S., Tang, A., Chen, M., Wilson, K. A., Collins, K. B., Heidecker, G. J., Fernandez, V. R., Perry, H. C., Joyce, J. G., Grimm, K. M., Cook, J. C., Keller, P. M., Kresock, D. S., Mach, H., Troutman, R. D., Isopi, L. A., Williams, D. M., Xu, Z., Bohannon, K. E., Volkin, D. B., Montefiori, D. C., Miura, A., Krivulka, G. R., Lifton, M. A., Kuroda, M. J., Schmitz, J. E., Letvin, N. L., Caulfield, M. J., Bett, A. J., Youil, R., Kaslow, D. C., and Emini, E. A. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415(6869), 331-5
78. Singh, M., Cattaneo, R., and Billeter, M. A. (1999). A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 73(6), 4823-8
79. Skiadopoulos, M. H., Durbin, A. P., Tatem, J. M., Wu, S. L., Paschalis, M., Tao, T., Collins, P. L., and Murphy, B. R. (1998). Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol 72(3), 1762-8
80. Skiadopoulos, M. H., Surman, S., Tatem, J. M., Paschalis, M., Wu, S. L., Udem, S. A., Durbin, A. P., Collins, P. L., and Murphy, B. R. (1999a). Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold- passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 73(2), 1374-81
81. Skiadopoulos, M. H., Surman, S. R., Riggs, J. M., Collins, P. L., and Murphy, B. R. (2001). A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys. J Virol 75(21), 10498-504
82. Skiadopoulos, M. H., Surman, S. R., Riggs, J. M., Orvell, C., Collins, P. L., and Murphy, B. R. (2002). Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology 297(1), 136-52
83. Skiadopoulos, M. H., Tao, T., Surman, S. R., Collins, P. L., and Murphy, B. R. (1999b). Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine 18(5-6), 503-10
84. Spielhofer, P., Bachi, T., Fehr, T., Christiansen, G., Cattaneo, R., Kaelin, K., Billeter, M. A., and Naim, H. Y. (1998). Chimeric measles viruses with a foreign envelope. J Virol 72(3), 2150-9
85. Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., and Bell, J. C. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6(7), 821-5
86. Stope, M. B., Karger, A., Schmidt, U., and Buchholz, U. J. (2001). Chimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteins. J Virol 75(19), 9367-77
87. Takeda, M., Pekosz, A., Shuck, K., Pinto, L. H., and Lamb, R. A. (2002). Influenza A virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 76(3), 1391-9
88. Tao, T., Davoodi, F., Cho, C. J., Skiadopoulos, M. H., Durbin, A. P., Collins, P. L., and Murphy, B. R. (2000a). A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 18(14), 1359-66
89. Tao, T., Skiadopoulos, M. H., Davoodi, F., Riggs, J. M., Collins, P. L., and Murphy, B. R. (2000b). Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates. J Virol 74(14), 6448-58
90. Tao, T., Skiadopoulos, M. H., Davoodi, F., Surman, S. R., Collins, P. L., and Murphy, B. R. (2001). Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone. Vaccine 19(27), 3620-31
91. Tao, T., Skiadopoulos, M. H., Durbin, A. P., Davoodi, F., Collins, P. L., and Murphy, B. R. (1999). A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge. Vaccine 17(9-10), 1100-8
92. Taqi, A. M., Abdurrahman, M. B., Yakubu, A. M., and Fleming, A. F. (1981). Regression of Hodgkin's disease after measles. Lancet 1(8229), 1112
93. Techaarpornkul, S., Barretto, N., and Peeples, M. E. (2001). Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol 75(15), 6825-34
94. Vongpunsawad, S., Oezgun, N., Braun, W. and Cattaneo, R. (2004). Selectively receptor-blind measles viruses: identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol, 78(1), 1
95. Wang, Z., Hangartner, L., Cornu, T. I., Martin, L. R., Zuniga, A., Billeter, M. A., and Naim, H. Y. (2001). Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 19(17-19), 2329-36
96. Watanabe, T., Watanabe, S., Ito, H., Kida, H., and Kawaoka, Y. (2001). Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. J Virol 75(12), 5656-62
97. Wertz, G. W., Moudy, R., and Ball, L. A. (2002). Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J Virol 76(15), 7642-50
98. Wertz, G. W., Perepelitsa, V. P., and Ball, L. A. (1998). Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci USA 95(7), 3501-6
99. Yonemitsu, Y., Kitson, C., Ferrari, S., Farley, R., Griesenbach, U., Judd, D., Steel, R., Scheid, P., Zhu, J., Jeffery, P. K., Kato, A., Hasan, M. K., Nagai, Y., Masaki, I., Fukumura, M., Hasegawa, M., Geddes, D. M., and Alton, E. W. (2000). Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 18(9), 970-3
100. Yu, D., Shioda, T., Kato, A., Hasan, M. K., Sakai, Y., and Nagai, Y. (1997). Sendai virus-based expression of HIV-1 gp120: reinforcement by the V(-) version. Genes Cells 2(7), 457-66
101. Zheng, H., Palese, P., and Garcia-Sastre, A. (2000). Antitumor properties of influenza virus vectors. Cancer Res 60(24), 6972-6
102. Zorn, U., Duensing, S., Langkopf, F., Anastassiou, G., Kirchner, H., Hadam, M., Knuver-Hopf, J., and Atzpodien, J. (1997). Active specific immunotherapy of renal cell carcinoma: cellular and humoral immune responses. Cancer Biother Radiopharm 12(3), 157-65